These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9193736)

  • 61. Neuroendocrine responses to serotonergic agents in alcoholics.
    Lee MA; Meltzer HY
    Biol Psychiatry; 1991 Nov; 30(10):1017-30. PubMed ID: 1756196
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment.
    Wik G; Wiesel FA; Eneroth P; Sedvall G; Aström G
    Acta Psychiatr Scand; 1986 Aug; 74(2):161-7. PubMed ID: 2877544
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Decreased serotonin2C receptor responses in male patients with schizophrenia.
    Lee MA; Jayathilake K; Sim MY; Meltzer HY
    Psychiatry Res; 2015 Mar; 226(1):308-15. PubMed ID: 25650049
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low HDL cholesterol, aggression and altered central serotonergic activity.
    Buydens-Branchey L; Branchey M; Hudson J; Fergeson P
    Psychiatry Res; 2000 Mar; 93(2):93-102. PubMed ID: 10725526
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathology.
    Naber D; Albus M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Wissmann J; Ackenheil M
    Psychiatry Res; 1985 Nov; 16(3):207-19. PubMed ID: 2868473
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of the placebo control condition in neuroendocrine challenge studies.
    Thompson PA; Maes M; Meltzer HY
    Psychiatry Res; 1994 Jun; 52(3):317-26. PubMed ID: 7991724
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Subjective neuroleptic response and treatment outcome under open and double-blind conditions--a preliminary report.
    Pi E; Sramek J; Johnson T; Herrera J; Heh C; Costa J; Cutler N; Ananth J
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):921-8. PubMed ID: 1980542
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of serotonin in schizophrenia. New findings.
    Iqbal N; Asnis GM; Wetzler S; Kay SR; van Praag HM
    Schizophr Res; 1991 Sep; 5(2):181-2. PubMed ID: 1931810
    [No Abstract]   [Full Text] [Related]  

  • 69. Neuroendocrine evaluation of 5-HT1A function in male alcoholic patients.
    Pinto E; Reggers J; Pitchot W; Hansenne M; Fuchs S; Ansseau M
    Psychoneuroendocrinology; 2002 Oct; 27(7):873-9. PubMed ID: 12183221
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia.
    Lee HS; Bastani B; Friedman L; Ramirez L; Meltzer HY
    Biol Psychiatry; 1992 Mar; 31(5):460-70. PubMed ID: 1581424
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia.
    Magharious W; Goff DC; Amico E
    Psychiatry Res; 1998 Feb; 77(3):159-66. PubMed ID: 9707298
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hormonal responses to meta-chlorophenylpiperazine (m-CPP) are undiminished by acute m-CPP pretreatment.
    Coccaro EF; Kavoussi RJ; Trestman RL; Gabriel SM; Cooper TB; Siever LJ
    Psychiatry Res; 1996 May; 62(2):139-45. PubMed ID: 8771611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers.
    Lawlor BA; Radcliffe J; Martinez R; Sunderland T; Murphy DL
    Biol Psychiatry; 1997 Mar; 41(6):756-7. PubMed ID: 9067003
    [No Abstract]   [Full Text] [Related]  

  • 74. Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects.
    Lawlor BA; Sunderland T; Hill JL; Mellow AM; Molchan SE; Mueller EA; Jacobsen FM; Murphy DL
    Psychiatry Res; 1989 Jul; 29(1):1-10. PubMed ID: 2772095
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder.
    Levitan RD; Kaplan AS; Brown GM; Vaccarino FJ; Kennedy SH; Levitt AJ; Joffe RT
    Arch Gen Psychiatry; 1998 Mar; 55(3):244-9. PubMed ID: 9510218
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia.
    Angelopoulos EK; Markianos M; Daskalopoulou EG; Hatzimanolis J; Tzemos J
    Psychiatry Res; 2002 May; 110(1):9-17. PubMed ID: 12007589
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Naloxone treatment for five days ineffective in schizophrenia. Neuroendocrine actions of the opiate antagonist.
    Naber D; Münch U; Wissmann J; Grosse R; Ritt R; Welter D
    Acta Psychiatr Scand; 1983 Apr; 67(4):265-71. PubMed ID: 6305111
    [No Abstract]   [Full Text] [Related]  

  • 78. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia.
    Sumiyoshi T; Matsui M; Yamashita I; Nohara S; Uehara T; Kurachi M; Meltzer HY
    J Clin Psychopharmacol; 2000 Jun; 20(3):386-8. PubMed ID: 10831031
    [No Abstract]   [Full Text] [Related]  

  • 79. The role of serotonin in schizophrenia.
    Bleich A; Brown SL; Kahn R; van Praag HM
    Schizophr Bull; 1988; 14(2):297-315. PubMed ID: 3059473
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects.
    Lawlor BA; Sunderland T; Mellow AM; Hill JL; Newhouse PA; Murphy DL
    Biol Psychiatry; 1989 Mar; 25(6):679-86. PubMed ID: 2923931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.